Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country - Analysis and Forecast, 2024-2033

The Europe hereditary genetic testing market was valued at $7.13 billion in 2024 and is anticipated to reach $21.06 billion by 2034, witnessing a CAGR of 12.79% during the forecast period 2024-2034. The market in Europe is expanding rapidly due to continuous technological improvements. Genetic testing is now more accurate, efficient, and affordable thanks to advancements in genetic sequencing technologies, especially next-generation sequencing (NGS). Demand is being driven by growing awareness of the advantages of genetic testing for diagnosing and treating hereditary conditions among healthcare professionals and the public. Additionally, the need for early diagnosis and individualized treatment solutions is highlighted by the rising incidence of genetic disorders and hereditary cancers. The expanding applications of genetic testing, such as prenatal and newborn screening, oncology, and precision medicine, further bolster the market growth. The quality and dependability of genetic tests are guaranteed by regulatory support and harmonized European guidelines, which promote market expansion throughout the region.

Market Introduction

The market for hereditary genetic testing in Europe is growing quickly due to developments in genetic sequencing technologies, rising awareness, and a growing need for individualized medical care. In order to diagnose inherited disorders, detect genetic disease predispositions, and facilitate early interventions for conditions like rare genetic disorders, cystic fibrosis, and hereditary cancers, hereditary genetic testing is essential.

The accuracy, effectiveness, and affordability of genetic tests have increased dramatically with the widespread use of next-generation sequencing (NGS) technologies, opening up access to them for patients and healthcare professionals alike. Further propelling market expansion are government initiatives supporting newborn screening and carrier testing programs, as well as advantageous regulatory frameworks and reimbursement policies.

The rising incidence of genetic disorders and hereditary cancers is driving demand for comprehensive testing solutions. Additionally growing in popularity are direct-to-consumer (DTC) genetic testing services, which give people access to genetic information without a doctor's prescription. The market's scope is being further expanded by significant investments in reproductive health testing, oncology genetics, and personalized medicine.

The market for hereditary genetic testing is expected to grow steadily as long as Europe prioritizes precision medicine and early disease detection. This growth will be aided by technological advancements, harmonized regulations, and rising public awareness.

Market Segmentation:

Segmentation 1: by Genetic Testing Type

• Oncology Genetic Testing
• Cardiology Genetic Testing
• Neurology Genetic Testing
• Newborn Screening
• Prenatal Screening (NIPT) and Preimplantation Testing
• Rare Disease Testing
• Direct-to-consumer (DTC) Testing

Segmentation 2: by Country

• Germany
• U.K.
• France
• Netherlands
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe hereditary genetic testing market has been extensively segmented based on various categories, such as genetic testing type and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments.

Competitive Strategy: The Europe hereditary genetic testing market has numerous established players with product portfolios. Key players in the Europe hereditary genetic testing market analyzed and profiled in the study involve established players offering products for hereditary genetic testing.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Centogene AG
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd

This product will be delivered within 3-5 business days.